Constitutively activated FLT3 signaling is common in acute myeloid leukemia, and is currently under evaluation for targeted therapy, whereas little data is available in T-cell acute lymphoblastic leukemia (T-ALL). We analyzed 357 T-ALL cases for FLT3 mutations and transcript expression. FLT3 mutations (3% overall) and overexpression (FLT3 high expresser (FLT3 High )) were restricted to immature/TCRgd T-ALLs. In vitro FLT3 inhibition induced apoptosis in only 30% of FLT3 High T-ALLs and did not correlate with mutational status. In order to investigate the mechanisms of primary resistance to FLT3 inhibition, a broad quantitative screen for receptor kinome transcript deregulation was performed by Taqman Low Density Array. FLT3 deregulation was associated with overexpression of a network of receptor kinases (RKs), potentially responsible for redundancies and sporadic response to specific FLT3 inhibition. In keeping with this resistance to FLT3 inhibition could be reversed by dual inhibition of FLT3 and KIT with a synergistic effect. We conclude that immature T-ALL may benefit from multitargeted RK inhibition and that exploration of the receptor kinome defines a rational strategy for testing multitarget kinase inhibition in malignant diseases.
INTRODUCTION
T-cell acute lymphoblastic leukemias (T-ALLs) represent expansions of cells arrested at specific stages of thymic development, with the underlying genetic abnormality often determining the stage of maturation arrest. 1 Several recent studies used different approaches but all suggested the existence of an immature subtype (IM) of T-ALL.
2-5 IM T-ALLs lack expression of T-cell receptor (TCR) alpha-beta or gamma-delta, cytoplasmic TCR beta (cTCRb), and frequently CD4/8 and CD1a markers. In contrast, expression of CD13 and CD33 myeloid antigens markers, as well as 'myeloid' oncogenic lesions, such as MLL and CALM-AF10 rearrangements, are common and relatively specific to this subset of T-ALLs. IM T-ALL, early T-cell precursor leukemia or T/myeloid biphenotypic acute leukemia have been reported to respond poorly to chemotherapy and may therefore benefit from specific targeted therapy. [6] [7] [8] [9] Tyrosine kinase inhibitors may represent such agents, but efficient evaluation of their potential therapeutic impact requires their use in subsets of patients that are most likely to benefit. Constitutive receptor tyrosine kinase activation of the FLT3 pathway by internal tandem duplication (ITD), tyrosine kinase domain point mutation (D835Y) or an autocrine-loop has been reported in acute myeloid leukemia (AML) 10 and MLL rearranged or hyperdiploid B-cell precursor ALL. 11 Activating FLT3 mutations have been described in rare cases of T-ALL 12, 13 when they have been reported to be restricted to the CD117 þ subset in adults or associated with a CD4 þ /CD8 À phenotype in pediatric T-ALL, but these data remain controversial. 14 FLT3 autocrine activation has also been reported in over 70% of AML cases and represents an alternative mechanism for FLT3 oncogenic signaling, regardless of FLT3 mutational status. [15] [16] [17] In AML, FLT3 overexpression associated with autophosphorylation and sensitivity to FLT3 inhibition of the receptor and identified an unfavorable prognostic subgroup. 18 Little data is available, however, regarding FLT3 expression and receptor tyrosine kinase profiles in either normal human T-cell maturation or in T-ALL.
We assessed oncogenic FLT3 mutation/deregulation in a large series of T-ALL and identified a concerted activated receptor kinase (RK) signature as a mechanism for primary resistance to single-agent FLT3 inhibition, but sensitivity to dual agent inhibition, thus providing an original rationale for multi-kinase therapeutic strategies.
MATERIALS AND METHODS Patients
The study population included 357 unselected patients, consisting of 195 adults (X15 years) and 162 children (o15 years) with newly diagnosed T-ALL. Samples were collected centrally for molecular and cellular analysis, with the support of the adult (GRAALL) and children (FRALLE) protocols. Diagnosis of T-ALL was based on the World Health Organization consensus criteria, 19 defined by expression of cytoplasmic CD3, with neither expression of MPO nor strong expression of cytoplasmic CD79a. As such, mixed phenotype acute leukemias were excluded from the study, in favor of pure T-ALL. Maturation stage of arrest was specified further, based on expression of cTCRbF1 and surface TCR, as previously described.
Normal thymus samples were obtained from children undergoing cardiac surgery at the Necker-Enfants-Malades Hospital, with informed consent from the parents.
Molecular analysis (real-time quantitative PCR, FLT3 mutational status and Taqman Low Density Array (TLDA))
An unselected series of 357 T-ALLs with available cDNA were screened for FLT3 ITD and D835Y mutations, as previously described. 20 FLT3 transcript expression was quantified by real-time quantitative PCR for 301 cases. Molecular oncogenetic analyses (TLX1, TLX3, SIL-TAL and CALM-AF10) were performed centrally, as previously reported. 2, 3 Results of transcriptional analysis were expressed as target/reference transcript ratios. ABL and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were shown to be highly correlated, including for cases harboring the NUP-ABL abnormality, and as such were used as reference genes (Supplementary Figure S1) . Quantification of RK expression was performed on quality-controlled cDNA using predesigned TaqMan Low Density microfluidic cards (TLDA Human Protein Kinase Array; Applied Biosystems). Real-time measurements were performed using the ABI Prism 7900HT (Applied Biosystems, Foster City, CA, USA). Samples with GAPDH cycle thresholds superior to 21 were excluded from analysis. Each probe value was normalized with respect to GAPDH copy number and analyzed with 13 Dcycle threshold threshold to discard background noise. Reproducibility of measurements and correlation with classical real-time quantitative PCR experiments were validated (Supplementary Figure S2) .
Statistical analysis
All monoparametric measurement comparisons were determined using the Mann-Whitney test or the Student's test when the number of individuals was superior to 30 (PRISM software, Graphpad, La Jolla, CA, USA). Hierarchical classifications were performed using the Pearson's correlation coefficient as a similarity metric with an average linkage algorithm as described. 21 Unsupervised selection of transcripts used to determine the RK signature was performed by removing gene transcripts that had s.d. of observed values over the whole series below o1.5.
Cell cultures
Cell culture was performed by maintaining plated thawed primary T-ALL cells in RPMI medium with 10% fetal bovine serum supplemented with human recombinant stem cell factor (SCF) (2 ng/ml), FLT3 ligand (FL) (5 ng/ml) and interleukin 7 (5 ng/ml). Dimethyl sulfoxide or increasing concentrations of FLT3-specific inhibitor (CEP701 or AC220) were added to cell cultures 3 h after platting cells. T-cell blasts were analyzed after 48 h of culture by flow cytometry using annexin V APC (Bender MedSystems, Vienna, Austria) and propidium iodide (BD-Pharmingen, San Jose, CA, USA) immunostaining. To assess apoptosis attributable to CEP701, results were plotted for each sample as percentage of untreated control (dimethyl sulfoxide). Immature T cells were considered sensitive as regards to CEP701 exposure when demonstrating o70% of cell viability as compared with untreated cells. The EOL cell line was used as an external control for CEP701 efficiency.
Analysis of combined drug effects
Individual drugs were tested to determine the dose required to induce apoptosis of cells to 50% of untreated controls (ED50) in an annexin V/ propidium iodide assay. Cells were treated with incremental concentrations of drugs but fixed ratios between individual drugs. Results were analyzed using the median-effect method of Chou and Talalay 22, 23 to produce isobolograms and calculate combination indices (Calcusyn Software; Biosoft, Cambridge, UK). The combination index was calculated based on the conservation assumption of mutually nonexclusive drug interactions. The combination index provides a numerical description of the effects of a drug combination: a combination index value ¼ 1, o1 or 41 predicts an additive, synergic or antagonist effect of drug combination, respectively, at the particular ratio and concentration examined.
Protein expression analysis and cell sorting FLT3 and KIT protein expression was analyzed by flow cytometry with a surface-staining protocol using FLT3/CD135 (clone 4G8) and KIT/CD117 (clone 104D2) phycoerythrin or PE-Cy7 (BD Biosciences, San Jose, CA, USA) antibody conjugates. All immunophenotypic analyses were performed by gating live blast T cells based on their pattern of CD45 and cytoplasmic CD3 expression. Stained samples were analyzed with a FACS Canto II (BD Biosciences). Thymic cells were sorted with a combination of CD3, CD4, CD8, CD34, CD1a and CD45 fluorochrome-labeled antibodies using a FACS Aria II cell-sorter (BD Biosciences) (Supplementary Figure S3) . Western blotting of FLT3 was performed using anti-FLT3 antibody (clone S18; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-phosphotyrosine (clone 4G10) as previously described. 24 Phosphorylation of KIT was analyzed using anti-phospho-c-Kit (Tyr719) (Cell Signaling Technology, Berverly, MA, USA) as previously reported. 25 Flow-cytometry monitoring of phosphoepitopes of FLT3 and downstream signaling molecules was performed using a polyclonal antiphospho-FLT3 (Y591) Alexa Fluor 488 (Cell Signaling Technology), monoclonal anti-phospho-STAT5 (Y694) Alexa Fluor 647 (Clone 47; BD Biosciences) and monoclonal anti-phospho-ERK1/2 (T202/Y204) Alexa Fluor 647 (Clone 20a, BD Biosciences). Leukemic samples were incubated in culture medium for 3 h and then secondarily subjected to different combinations of activators and/or inhibitors; FL, CEP701 and AC220. Monitoring of phospho-protein state was performed after 30 min of exposure for FLT3, and 1 h for ERK and STAT5 molecules. Cells were immediately fixed by addition of BD CytoFix fixation buffer (BD Biosciences) into the culture well and then incubated for 15 min at 37 1C. After washing, cells were permeabilized using BD PhosFlow Perm Buffer III (BD Biosciences) according to the manufacturer's instructions. Samples were then stained using the above-mentioned reagents added with a backbone combination of markers including CD45 V500 (HI30) and CD3 PE (UCHT1) for gating of blast cells. Samples were analyzed using a FACS Canto II (BD Biosciences). Data were processed using Cytobank software. 26 Changes in phosphorylation of signaling proteins following activator and/or inhibitor exposure were calculated using the log 2 ratio of the median fluorescence intensity of cells stained with anti-phosphoepitope antibody versus isotype controls, and expressed in a color scale in the corresponding figure.
RESULTS

FLT3 mutations in T-ALL
FLT3 ITD (nine cases) and D835Y mutation (one case) were detected in 10 (3%) out of 357 T-ALL cases. Characteristics of T-ALL patients carrying FLT3 mutations according to their phenotypic and oncogenetic features are reported in Table 1 . FLT3 mutations A rationale for multitarget kinase inhibition L Lhermitte et al have been reported to be limited to a CD117 þ subset of adult T-ALLs 12 and CD4 þ /CD8 À phenotype in pediatric T-ALLs. 13 In our overall series, 6 of the 10 FLT3-mutated cases (2/4 adult cases) were CD117 À and only 4/48 CD117 þ T-ALLs (2/25 adults cases) demonstrated FLT3 mutation compared with 6/294 CD117 À T-ALLs. Moreover, although a CD4 þ /CD8 À phenotype was more common in FLT3 ITD/D835Y than FLT3 WT (FLT3 WT ) (Table 1) , the majority were CD4/8 double negative and one was CD4 þ /8 þ . All the FLT3-mutated cases were CD34 þ and 9/10 expressed myeloid markers, compared with 40% and 33% of the FLT3 WT group, respectively. Interestingly, FLT3 ITD and D835Y (FLT3 Mut ) were observed in 8/120 (7%) IM T-ALL, 2/57 (3.5%) TCRgd þ T-ALL, but none of the 180 ab-lineage T-ALL (Po0.01). These data strongly suggest that FLT3 ITD/D835Y mutations are restricted to the immature/TCRgd lineage as are MLL and CALM-AF10 fusion transcripts. 3, 27 As expected, all the FLT3 Mut cases demonstrated high FLT3 transcript expression compared with FLT3-unmutated cases (Table 1) . However FLT3-unmutated T-ALLs harbored a continuous pattern of FLT3 transcript expression, including highlevel expression (see below).
FLT3 expression in normal and malignant T cells FLT3 transcripts were then assessed using quantitative reverse transcription PCR in 301 T-ALL and compared with whole-human thymus and sorted thymic subpopulations. During normal thymopoiesis, the highest FLT3 expression was observed in the most immature CD34 þ thymic population, with a progressive decrease during maturation (Figure 1a ). FLT3 expression in T-ALLs was a continuous spectrum, including cases expressing high levels of FLT3 transcripts compared with normal thymocytes. In all, 67 (22.2%) out of the 301 evaluated cases were classified as FLT3 high expresser (FLT3 High ) on the basis of FLT3 transcript expression levels that exceeded the mean value in normal thymocytes by more than fivefold (threshold cut defined at 88.3%) (Figure 1a ). FLT3 expression in these cases was at least twofold higher than the mean value observed in immature CD34 þ thymocytes (P ¼ 0.001). As expected, all of the 10 FLT3
Mut cases were classified as FLT3
High T-ALLs. The FLT3 High cases demonstrated a higher rate of CD34, CD117 and myeloid antigen expression, as compared with low FLT3-expresser T-ALLs (FLT3 Low ) ( Table 2 ). Similar levels of FLT3 expression between FLT3 Low T-ALLs and normal thymic subpopulations suggest that these cases may express physiological rather than oncogenic FLT3. Within FLT3 WT cases, IM and TCRgd þ cases showed higher FLT3 transcript levels compared with ab-lineage cases ( Figure 1b and Table 2 ). In keeping with this, FLT3 transcript expression was higher in oncogenetic groups associated with a TCRgd lineage orientation, such as CALM-AF10 3 and TLX3 28 and lower in oncogenetic groups with an ab-lineage orientation such as SIL-TAL1 29 ( Figure 1c) . These data were then confirmed at the protein level when 54% FLT3
WT/High T-ALLs harbored a receptor detectable at the cell surface (Table 2 Low T-ALLs were CD135/FLT3 negative, and only 5% of the latter showed FLT3 expression. FLT3 protein expression was not found in normal human thymus, even in immature subpopulations (Supplementary Figure 4A) . Overall, FLT3 protein expression appeared ectopic and overrepresented in the FLT3
High subset of T-ALLs. As such, these FLT3
High T-ALLs could be considered to express deregulated FLT3 and suggests that FLT3 expression in immature and TCRgd T-ALLs is probably oncogenic.
Oncogenic FLT3 activation in FLT3
High T-ALLs
In order to further explore the potential oncogenic effect of FLT3 overexpression, we then checked whether FLT3 overexpression and/or mutation was associated with constitutive activation of the 
receptor. As expected, FLT3
Low T-ALLs did not show constitutive receptor phosphorylation. In contrast, FLT3
High T-ALLs demonstrated phosphorylation of the receptor, irrespective of their mutational status, in line with similar data in AML 18 ( Figure 2b ). We then investigated the phosphorylation status of ERK and STAT5 signaling molecules as downstream effectors of the FLT3 pathway. [30] [31] [32] We opted for a flow-cytometric approach in order to optimize the limited material availability and focus on blast T cells. As expected, FLT3
Mut/High cases harbored constitutive phosphorylation of FLT3, and downstream ERK and STAT5 molecules, with a significant increase in response to FL (Figure 2c ). As an internal control, no FLT3 phosphorylation was detected in FLT3 Low cases. The latter could display constitutive activation of ERK and STAT5 molecules, possibly dependent on the alternative signaling pathways, but this was not influenced by FL adjunction. Finally, FLT3
WT/High T-ALLs demonstrated constitutive activation of FLT3, STAT5 and ERK molecules, which was dramatically enhanced when FL was added to the culture medium. These data favored ectopic, functional and oncogenic FLT3 signaling in this subset of T-ALL. In keeping with this, Pim-1 transcript levels, considered as a functional readout for FLT3 oncogenic activation, [33] [34] [35] were significantly higher in the FLT3 High group as compared with FLT3 Low cases (P ¼ 0.02; Figure 2d ). Altogether, our results suggest that upregulation of FLT3 is a common abnormality in T-ALL and is associated with activation of the receptor, as in AML. 18 As such, FLT3 High T-ALLs, which are mostly immature, could be eligible for tyrosine kinase inhibitortargeted therapy.
Heterogeneous sensitivity of FLT3 high-expressing leukemic T cells to FLT3 inhibition To determine whether FLT3 might be a target for therapy in T-ALL, we then assessed the efficiency of FLT3 inhibition on primary cultured T-ALL blast cells using the CEP701 small molecule. showed in vitro sensitivity to CEP701 (Figures 3a and b) . As CEP701 was reported to have weak FLT3 specificity, we then evaluated a more selective FLT3 inhibitor, AC220. 36, 37 Both CEP701-sensitive FLT3 High T-ALLs remained significantly sensitive to AC220 inhibition (Figure 3c ). In addition, three CEP701-resistant FLT3
WT/High cases (UPN 539, 401 and 85) were evaluated using AC220; all remained resistant to FLT3 inhibition (data not shown). Of note, resistance was also not reversed on culture of primary blast cells in the absence of FL (Figure 3d ) and reversion of the phosphorylation state of FLT3 was evidenced for both CEP701 and AC220 (Figure 3e) , whether in the presence or absence of FL (Figure 3f ), including in cases harboring resistance to FLT3 inhibition. To decipher the biological relevance of this heterogeneous sensitivity to FLT3 inhibition, we hypothesized that FLT3 may not be deregulated in isolation but rather in concert with other signaling RKs, thus bypassing the inhibition of FLT3 in resistant cases.
Concerted transcriptional regulation of RK in FLT3
High T-ALLs regardless of the FLT3 mutational status To screen for potential co-deregulated RK, we quantified transcripts from 65 human RK 38 Figure S2A) . Moreover, intra-and inter-experimental controls demonstrated high reproducibility of the measurements, which allowed precise comparisons of receptor tyrosine kinase profiles between individuals (Supplementary Figure S2B) .
Of the 65 RK, 16 were not expressed at significant levels in either normal thymus or T-ALLs. Sixteen RKs were not expressed in the thymus but were aberrantly expressed in at least one case of T-ALL. In particular, RKs, such as TIE1, NTRK1, TYRO3 and MERTK, were overexpressed in a significant number of T-ALLs (9-11). Several other RKs were expressed in the thymus and demonstrated deviant expression patterns in T-ALL. TGFBRI, TGFBRII, BMPR2 and DDR1 were underexpressed in most T-ALLs. In contrast, EPHB4, FGFRL1, KIT, TIE1, NTRK1 and MERTK were Low subset and FLT4 and LTBP1, which were overexpressed in both groups (Figure 4 and Supplementary Figure S5 ).
Unsupervised analysis of the receptor kinome revealed two distinct clusters, which spontaneously split RK multitargeting could partially reverse leukemic T-cell resistance CEP701-sensitive and -resistant FLT3
High cases did not split apart and intermingled within the FLT3 High cluster. We then hypothesized that, despite sharing a common biology, these cases may thus display variable dependence on individual RK identified within the FLT3 High -associated RK signature. In order to reverse resistance to FLT3 inhibition, we compared individual receptor kinomic specificities of CEP701-resistant and -sensitive cases. Interestingly, among the five FLT3
High expressers explored by TLDA, the two cases that were sensitive to FLT3 inhibition expressed low level KIT transcripts, whereas the three resistant cases exhibited high level of KIT (Figure 4) . Expression was confirmed at the protein level (Figure 5a ). The levels of KIT expression (Figure 5b) were, as for FLT3, higher than those seen in thymic subsets and, as such, were considered supraphysiological (Figure 5b and Supplementary Figure S4B) . Pharmacological inhibition of KIT using STI571 or AB1010 39 could be tested in three resistant FLT3
High cases. One case remained resistant either to FLT3, KIT or to coinhibition of both of these RKs. Interestingly, leukemic cell survival was impaired in response to KIT inhibition for the two other cases and either a potentiation or synergistic effect was observed when combining FLT3 and KIT inhibition for these patients (Figures 5c and d) , supporting a reversion of resistance by targeting several converging RKs. In line with this, these cases showed concomitant protein expression of both FLT3 and KIT receptors (Figure 5e ), further excluding a mosaic expression and a simple additive effect of RK coinhibition. At the biochemical level, we confirmed significant inhibition of KIT upon exposure to AB1010, but not AC220, using drug doses necessary for synergistic impairment of survival by RK coinhibition (Figure 5f ). Taken together, these data favor co-deregulation of RK networks in T-ALL and suggest that pattern of RK expression in
FLT3
High T-ALLs could provide the basis for rational multitargeted RK therapy in immature T-ALLs.
DISCUSSION
We demonstrate here that FLT3 expression is common in immature and gd-lineage T-ALL and that FLT3 mutations are restricted to these subsets. Response to CEP701, one of the FLT3 inhibitors, 40 was restricted to FLT3 High T-ALLs but was sporadic and independent of mutational status, probably because FLT3 expression was frequently accompanied by deregulation of other RK, including KIT. The synergic cytotoxic effect of FLT3 and KIT inhibitors provide proof of a rationale for multi-RK targeting in immature T-ALL.
FLT3 mutations (D835Y and ITD) were infrequent (3%) in T-ALL and were restricted to cases with an immature/TCRgd phenotype but were not restricted to CD117 þ or CD4 þ /8 À T-ALLs, as previously reported. 12, 13 It is likely that high-level FLT3 expression, currently idiopathic, has oncogenic significance because the levels were higher than those found in the thymus and its subpopulations, including the most immature (CD34 þ ) fraction, and also segregated with the same immature/TCRgd phenotype. These data are coherent with transcriptional profiling identification of FLT3 expression as a characteristic contributor to the signature of immature T-ALL. 5 FLT3 overexpression in T-ALL was associated with constitutive activation of the receptor, as evidenced by phosphorylation of the receptor. Few cases of T-ALL could be tested for FLT3 phosphorylation, given the limited availability of material suitable for phosphoepitope analysis by western blot. T-ALL blasts usually demonstrate a short life expectancy ex-vivo that may alter phophoproteomic profiles and no FLT3
High T-ALL cell line has been identified (see Supplementary Figure S6 ). Our observation favors oncogenic activation of the FLT3 pathway in FLT3
Mut/High and at least a subset of FLT3
WT/High T-ALL. The high level of PIM-1 transcripts in FLT3 High T-ALLs is in keeping with this, because PIM-1 is induced by FLT3 oncogenic activation. [33] [34] [35] This observation is also consistent with previous studies showing that FLT3 overexpression in AML is associated with constitutive phosphorylation of the receptor, a dismal prognosis, and sensitivity to kinase inhibition. 18 Immature T-ALL is also related to a poor response to chemotherapy, in both adults and children, [6] [7] [8] [9] and may therefore benefit from FLT3 inhibition.
Our in vitro experiments demonstrated sensitivity and induction of apoptosis in primary T-ALL blast upon exposure to CEP701. Response was restricted to FLT3
High -expressing cases, in keeping with an oncogenic role for the FLT3 pathway in these cases, but was sporadic (two out of six FLT3 High T-ALLs tested) and independent of mutational status. Primary resistance to FLT3 inhibitors in AML, observed in approximately 30% of FLT3-mutated cases, 41 has been correlated with the type of mutation [42] [43] [44] or considered to reflect dependence on the FLT3 molecule but not on FLT3 kinase activity. 45 Two recent studies also suggested that secondary resistance was associated in a significant number of cases with increases in circulating FL concentrations in vivo. 46, 47 Failure to reverse resistance to CEP701 in the absence of FL did not confirm this hypothesis in our in vitro T-ALL model. Inherent resistance has also been proposed to be linked to the compensatory activation pathways, rendering leukemic cells independent of FLT3 activation. 48 Our data are in keeping with this. We used a simple assay to define the receptor kinome signature of individual T-ALLs and screen RKs eligible for multitargeting. This demonstrated that FLT3 deregulation is virtually always associated with deregulation of a RK network and that virtually all T-ALLs display a receptor kinome, which is distinct from normal thymocytes. The exact oncogenic basis for this kinome signature remain to be further investigated.
As RK signatures in FLT3-expressing immature/TCRgd T-ALLs are reproducible, it is probable that selective inhibition will not lead to Figure 4 . RK profiles of human T-ALL samples and thymic subpopulations. Hierarchical classification based on RK transcript levels shows that FLT3 High/Mut and FLT3 High/WT share similar pattern of RK expression, which is distinguishable from both FLT3 Low cases and normal thymocytes. The heat map represents the relative and differential expression of each RK gene and is normalized relative to whole-thymic expression, shown here in gray as the reference. Over-or underexpression as compared with this reference is highlighted in red and blue, respectively, with depth of color reflecting deviation from the normal thymocytes reference. Each color change reflects a 1-delta cycle threshold step change in gene expression. Transcripts used to determine the RK signature were selected in an unsupervised manner by removing gene transcripts that had s.d. of observed values over the whole series o1.5. Complete classification based on the entire set of RK transcripts without RK selection provides similar results and is shown in Supplementary figure S4.
cell death, due to unmodified activity of unaffected RK. Different RK may convergently affect distinct signaling nodes, 49 with a significant functional redundancy. Several recent studies used multitarget kinase inhibitors and demonstrated synergistic cytotoxicity against blast cells, thereby suggesting that simultaneous inhibition of multiple key target kinases could be an efficient therapeutic strategy. 50, 51 One elegant study in glioblastoma highlighted coactivation of multiple RK, leading to redundant inputs and limiting efficacy of targeting single RK. 52 Noteworthy, resistance to single agents in this study could be reversed using multiple RK-targeting agents. In keeping with this, simultaneous FLT3 and KIT inhibition by CEP701 and AB1010 was synergic in one T-ALL, providing proof of concept for RK multitargetting in immature, FLT3
High T-ALLs. The identification of coexpressed RKs, such as EPHB4, NTRK1, and the previously reported MERTK, also represent candidate targets for RK-inhibition therapy. 53 Taken together, we have identified concerted receptor kinome deregulation in FLT3
High IM/TCRgd T-ALLs, which may explain why single-agent inhibition is less appropriate than multitarget RK inhibition. This RK screening procedure, applied here to human T-ALL samples, may be extended to other hematological or solid malignancies to design and test new multitargeted therapies. and isobologram curve (right) for the effect of AC220 and AB1010 on induction of apoptosis. The latter was measured by annexin V/ propidium iodide-based assay on primary blast cells from UPN_647, and results were calculated using CalcuSyn software (see Materials and Methods). The experimental points fall to the left of the predicted line of additive effect, indicating a synergistic interaction of AC220 and AB1010. This is reflected by combination index (CI) values reported in the table below the curves, reflecting an even more synergistic effect as the CI value falls o1. D, drug dose; Fa, fraction affected; fu, fraction unaffected. (e) Flow-cytometric analysis of FLT3 and KIT protein expression. Results indicate coexpression of both RK receptors by T-ALL blast cells. (f ) Western blot analysis of KIT phosphorylation upon drug exposure (AB1010 10 mM and AC220 50 nM) showed significant C-Kit phosphorylation decrease after AB1010 but not AC220 exposure.
